Lys Therapeutics
Biotech developing an antibody to treat blood-brain barrier dysfunction and neuroinflammation in neurological diseases
Highlights
- New on EvolcAdded 2026-11-02
About Lys Therapeutics
Lys Therapeutics is a biotechnology company developing antibody therapies that target blood-brain barrier dysfunction and neuroinflammation in severe neurological diseases. Its lead candidate, LYS241, is a humanized, Fc-silent monoclonal antibody designed to block the interaction between tPA and NMDA receptors from within blood vessels, without needing to cross the blood-brain barrier.
The company is at the preclinical stage and is preparing a Phase 1a/1b program. Its priority indications are Parkinson's disease, multiple system atrophy and acute ischemic stroke, with preclinical research in multiple sclerosis supporting further opportunities. Initial clinical administration is planned intravenously, with subcutaneous delivery envisaged for longer-term treatment.
The company was founded in 2021 and is headquartered in Caen, France. Its management team includes co-founders Dr. Manuel Blanc (CEO and President) and Philippe Dujardin (CFO), and its board includes independent members. The scientific advisory board includes neurologists from Austria, France and the Netherlands.
Product: LYS241, a humanized Fc-silent IgG1 monoclonal antibody targeting tPA–NMDA receptor interaction in neurovascular disease.
Jobs at Lys Therapeutics
Leadership
- Manuel Blanc · Co-founder, Chief Executive Officer and President, Member of the Board of DirectorsSource: company website
- Jordan Guyon · Chief Operating OfficerSource: company website
- Philippe Dujardin · Co-founder, Chief Financial Officer, Member of the Board of DirectorsSource: company website
More biotech & pharma companies
Maat Pharma
Develops microbiome-based cancer therapeutics for patients with severe oncology diseasesNew on EvolcMabqi
Discovers and develops therapeutic antibodies for biopharmaceutical partners and oncology treatment programsNew on EvolcMabsilico
AI-based antibody candidate design for biotech and pharma companies, with candidates delivered in 21 daysNew on EvolcMetafora Biosystems
Develops single-cell metabolic testing and analysis for diagnostic and cell therapy applicationsNew on EvolcMexbrain
Develops dialysis-based medical devices to remove excess metals from the blood of patients with metal-related conditionsNew on EvolcMicrophyt
Microalgae-based ingredients for health, nutrition, well-being and beauty businessesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.